Clinical Trial Update: Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy [NA]

View source ↗

Summary

Prospective clinical study evaluating orelabrutinib in combination with rituximab for primary marginal zone lymphoma that failed or was not suitable for local t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Marginal Zone Lymphoma | NA | Status: RECRUITING